BrainStorm Cell Therapeutics Inc. (BCLI) stock
BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.01 (-1.17%)
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
BrainStorm Cell Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
No revenue figures for BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?